Holen Sie sich die Stockscreener-App
0.594
0.08%
-0.0065
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.6005
Offen:
$0.601
24-Stunden-Volumen:
28,692
Relative Volume:
0.05
Marktkapitalisierung:
$16.36M
Einnahmen:
$5.61M
Nettoeinkommen (Verlust:
$-55.45M
KGV:
-0.2311
EPS:
-2.5703
Netto-Cashflow:
$-42.35M
1W Leistung:
+3.54%
1M Leistung:
-12.06%
6M Leistung:
-28.49%
1J Leistung:
-50.41%
1-Tages-Spanne:
$0.5852
$0.61
1-Wochen-Bereich:
$0.58
$0.6169
52-Wochen-Spanne:
$0.4687
$2.19
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Firmenname
Citius Pharmaceuticals Inc
Sektor
Branche
Telefon
(908) 967-6676
Adresse
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.5958 | 16.49M | 5.61M | -55.45M | -42.35M | -2.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
522.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.43 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.02 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.69 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.08 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
Citius Pharmaceuticals stock stabilizes as investors look to next data catalysts - AD HOC NEWS
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire
Citius Pharmaceuticals Inc. Warrant (CTXRW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Citius Pharmaceuticals Inc. Warrant (CTXRW) Key Financial Ratios – Valuation, Profitability & More - Value Research
CTXR Should I Buy - Intellectia AI
CTXR Stock Price, Quote & Chart - ChartMill
Citius Pharmaceuticals Inc. (CTXR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Citius (CTXR) Earnings Report: Reported EPS Misses Expectations in the Latest Reading; Price Reaction: Shares Move 0.07% Higher in the Current UpdateFinal Results - vinanet.vn
Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq gives Citius (NASDAQ: CTXR) more time before $1 delisting risk - Stock Titan
H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy By Investing.com - Investing.com South Africa
Citius (CTXR) Market-Day Review: Finishes 1.78% Higher at $0.57 in the Latest Session; Key Levels: the Near-Term Reference Band Stretches From $0.54 to $0.60 in the Available RecordWMA Signal - vinanet.vn
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance
Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Clinical Focus Checkpoint Mean? - Kalkine Media
Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Program Priorities Checkpoint Mean? - Kalkine Media
Is Citius Pharmaceuticals (CTXR) Worth the Investment After Q3 E - GuruFocus
CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% While Stock Gains 3.0%Analyst Earnings Estimate - vinanet.vn
Citius Pharmaceuticals (CTXR) Gains 3% to $0.76 as Buyers Defend SupportBull Pennant - dars.gov.et
Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard
Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart
Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan
Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - The AI Journal
Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI
CTXR: LYMPHIR's launch drove $7.1M revenue and 77% gross margin, offset by higher launch costs - TradingView
Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan
Citius Oncology, Inc. Announces Appointment of Jonathan Peri, Ph.D., J.D., as Independent Director, Effective August 10, 2026 - marketscreener.com
Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan
CTXR Q3'26 Earnings: EPS estimate is (0.36) USD - TradingView
Citius Oncology appoints independent director Peri to board of directors - ROI-NJ
People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar
Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union
Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz
Citius Oncology appoints Jonathan Peri to board of directors - Investing.com
Citius Pharmaceuticals (CTXR) Edges Higher by 1.92%, Maintaining Position Above Key Support at $0.69TWAP Entry - vinanet.vn
BREAKING: THE PRINTING HAS STARTED! Robert De Niro (xWXxQcdGpe) - Mshale
CTXR Q4 2025 Earnings: EPS Misses Estimates by 45.04% as Shares Rise 6.23%Banking Earnings Report - vinanet.vn
Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Oncology of Cranford says commercial response to cancer treatment is strong - ROI-NJ
Citius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanks
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - Morningstar
Citius Pharmaceuticals (CTXR) Advances 5.7% to $0.63; Key Resistance at $0.66 in FocusGamma Flip Level - vinanet.vn
Citius Pharmaceuticals (CTXR) Tumbles 9.81% to $0.57 as Biotech Stock Approaches Critical SupportTake Profit Levels - vinanet.vn
CTXR Q4 2025 Earnings: Wider-than-Expected Loss Met with Positive Stock ReactionOne-Time Gain Impact - vinanet.vn
Citius Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals Inc (CTXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTXR|Citius Pharmaceuticals Inc|Price:0.738|Chg%:-0.027 - TradingKey
Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Pharmaceuticals Inc (CTXR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Pharmaceuticals Inc (CTXR) Institutional Confidence - TradingKey
Finanzdaten der Citius Pharmaceuticals Inc-Aktie (CTXR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):